Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Oct 14 (Reuters) — Pharming Group N.V.: Presents Positive Phase Ii Topline Data For Leniolisib In Genetic Pids With Immune Dysregulation At Esid 2026 Leniolisib Well-tolerated With Benefits In Immune Dysregulation Measures Mean Spleen Volume Reduction Of 26.4% In Phase Ii Leniolisib Trial Improvement In Liver Stiffness
Pharming presented positive topline data from its Phase II trial of leniolisib in genetically identifiable primary immunodeficiencies.
The company presented initial high-level results for leniolisib in genetic primary immunodeficiencies with immune dysregulation at ESID 2026.